Krystal Biotech will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York.
Quiver AI Summary
Krystal Biotech, Inc. announced its participation in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York, where company management will engage in a fireside chat at 3:55 pm ET and hold investor meetings throughout the day. A webcast of the chat will be available on the company's website. Krystal Biotech, a commercial-stage biotechnology firm based in Pittsburgh, focuses on developing genetic medicines for diseases with significant unmet medical needs. Its first product, VYJUVEK®, is recognized as the first redosable gene therapy and is approved in the U.S., Europe, and Japan for treating dystrophic epidermolysis bullosa. The company continues to advance its clinical and preclinical pipeline of investigational therapies.
Potential Positives
- The participation in the 2026 Cantor Global Healthcare Conference highlights the company's commitment to engaging with investors and demonstrates transparency in its operations.
- The upcoming webcast of the presentation will increase accessibility for stakeholders, allowing for broader reach and engagement with potential investors and the public.
- Krystal Biotech's status as a fully integrated, commercial-stage biotechnology company with a focus on genetic medicines emphasizes its position in a market with high unmet medical needs, signaling growth potential.
- The success of VYJUVEK®, being the first-ever redosable gene therapy approved in major markets, reflects the company's innovative capabilities and drives investor interest in its future pipeline of genetic medicines.
Potential Negatives
- None
FAQ
When is Krystal Biotech participating in the Cantor Global Healthcare Conference?
Krystal Biotech will participate in the conference on September 10, 2026.
What time is the fireside chat scheduled for?
The fireside chat is scheduled for 3:55 PM ET on September 10, 2026.
Where can I access the webcast of the presentation?
The webcast will be available on the Company's website starting at 3:55 PM ET on September 10, 2026.
What is VYJUVEK®?
VYJUVEK® is the first redosable gene therapy approved for treating dystrophic epidermolysis bullosa in the US, Europe, and Japan.
What is Krystal Biotech's focus as a company?
Krystal Biotech focuses on discovering, developing, and commercializing genetic medicines for high unmet medical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KRYS Insider Trading Activity
$KRYS insiders have traded $KRYS stock on the open market 32 times in the past 6 months. Of those trades, 0 have been purchases and 32 have been sales.
Here’s a breakdown of recent trading of $KRYS stock by insiders over the last 6 months:
- DINO A ROSSI has made 0 purchases and 8 sales selling 25,000 shares for an estimated $8,227,952.
- KRISH S KRISHNAN (President and CEO) has made 0 purchases and 11 sales selling 25,000 shares for an estimated $7,702,983.
- SUMA KRISHNAN (President, R&D) has made 0 purchases and 11 sales selling 25,000 shares for an estimated $7,702,825.
- JOHN CHARLES THOMAS (EVP, General Counsel) has made 0 purchases and 2 sales selling 1,642 shares for an estimated $541,173.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$KRYS Hedge Fund Activity
We have seen 263 institutional investors add shares of $KRYS stock to their portfolio, and 165 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTOR CAPITAL, LLC added 700,714 shares (+350357.0%) to their portfolio in Q2 2026, for an estimated $260,434,372
- BELLEVUE GROUP AG removed 404,255 shares (-83.9%) from their portfolio in Q2 2026, for an estimated $150,249,455
- CITADEL ADVISORS LLC removed 383,779 shares (-99.3%) from their portfolio in Q1 2026, for an estimated $99,137,791
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 254,828 shares (+inf%) to their portfolio in Q2 2026, for an estimated $94,711,922
- BLACKROCK, INC. added 240,976 shares (+6.1%) to their portfolio in Q2 2026, for an estimated $89,563,549
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 213,833 shares (-18.5%) from their portfolio in Q2 2026, for an estimated $79,475,311
- PRICE T ROWE ASSOCIATES INC /MD/ added 202,326 shares (+41.7%) to their portfolio in Q2 2026, for an estimated $75,198,504
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$KRYS Price Targets
Multiple analysts have issued price targets for $KRYS recently. We have seen 4 analysts offer price targets for $KRYS in the last 6 months, with a median target of $369.5.
Here are some recent targets:
- Ritu Baral from TD Cowen set a target price of $403.0 on 06/18/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $361.0 on 06/16/2026
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $300.0 on 05/05/2026
- Yigal Nochomovitz from Citigroup set a target price of $378.0 on 05/05/2026
Full Release
PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 3:55 pm ET on Thursday, September 10, 2026 and will be posted on the Investors section of the Company’s website .
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK
®
, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit
www.krystalbio.com
to learn more or follow us on
LinkedIn
and
X
.
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
[email protected]
